# Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse

> **NCT00189553** · PHASE3 · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 976 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Pegylated liposomal doxorubicin
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00189553
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2009-01
- **Final completion:** 2012-06
- **Target enrollment:** 976 (ACTUAL)
- **Last updated:** 2014-01-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189553, "Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00189553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*